United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine capsules usp are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine capsules usp are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine capsules are indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine capsules are indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

nizatidine - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. nizatidine is contraindicated in patients with known hypersensitivity to the drug. because cross sensitivity in this class of compounds has been observed, h2-receptor antagonists, including nizatidine, should not be administered to patient

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 15 mg in 1 ml - nizatidineoral solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidineoral solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine oral solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine oral solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. in pediatric patients, nizatidine oral solution is indicated for ages 12 years and older. nizatidine oral solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esoph

United States - English - NLM (National Library of Medicine)

rebel distributors corp - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

proficient rx lp - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine capsules usp are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine capsules usp are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine capsules usp are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine capsules usp are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

dispensing solutions inc. - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 300 mg - nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.

United States - English - NLM (National Library of Medicine)

glenmark pharmaceuticals inc., usa - nizatidine (unii: p41pml4ghr) (nizatidine - unii:p41pml4ghr) - nizatidine 150 mg - nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active duodenal ulcer. in most patients, the ulcer will heal within 4 weeks. nizatidine capsules usp are indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. the consequences of continuous therapy with nizatidine for longer than 1 year are not known. nizatidine capsules usp are indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gerd. nizatidine capsules usp are indicated for up to 8 weeks for the treatment of active benign gastric ulcer. before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.